vs

Side-by-side financial comparison of LXP Industrial Trust (LXP) and Schrodinger, Inc. (SDGR). Click either name above to swap in a different company.

Schrodinger, Inc. is the larger business by last-quarter revenue ($87.2M vs $86.7M, roughly 1.0× LXP Industrial Trust). Schrodinger, Inc. runs the higher net margin — 37.3% vs 33.2%, a 4.1% gap on every dollar of revenue. On growth, Schrodinger, Inc. posted the faster year-over-year revenue change (-1.2% vs -14.0%). Over the past eight quarters, Schrodinger, Inc.'s revenue compounded faster (54.4% CAGR vs 0.3%).

LXP Industrial Trust is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality industrial real estate assets, primarily distribution centers, logistics facilities, and light industrial properties across key markets in the United States. Its tenant base covers e-commerce, third-party logistics, and advanced manufacturing sectors, delivering stable long-term returns for its investors.

Schrodinger, Inc. is a leading provider of advanced computational chemistry and physics software platforms, along with related consulting services, focused on accelerating drug discovery and novel materials development. Its solutions are adopted by biopharmaceutical companies, chemical manufacturers, academic research institutions and government entities across North America, Europe and Asia Pacific to cut R&D costs and shorten innovation cycles.

LXP vs SDGR — Head-to-Head

Bigger by revenue
SDGR
SDGR
1.0× larger
SDGR
$87.2M
$86.7M
LXP
Growing faster (revenue YoY)
SDGR
SDGR
+12.8% gap
SDGR
-1.2%
-14.0%
LXP
Higher net margin
SDGR
SDGR
4.1% more per $
SDGR
37.3%
33.2%
LXP
Faster 2-yr revenue CAGR
SDGR
SDGR
Annualised
SDGR
54.4%
0.3%
LXP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LXP
LXP
SDGR
SDGR
Revenue
$86.7M
$87.2M
Net Profit
$28.8M
$32.5M
Gross Margin
81.5%
65.7%
Operating Margin
34.6%
-19.7%
Net Margin
33.2%
37.3%
Revenue YoY
-14.0%
-1.2%
Net Profit YoY
180.8%
EPS (diluted)
$0.45

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LXP
LXP
SDGR
SDGR
Q4 25
$86.7M
$87.2M
Q3 25
$86.9M
$54.3M
Q2 25
$87.7M
$54.8M
Q1 25
$88.9M
$59.6M
Q4 24
$100.9M
$88.3M
Q3 24
$85.6M
$35.3M
Q2 24
$85.8M
$47.3M
Q1 24
$86.3M
$36.6M
Net Profit
LXP
LXP
SDGR
SDGR
Q4 25
$28.8M
$32.5M
Q3 25
$36.3M
$-32.8M
Q2 25
$29.1M
$-43.2M
Q1 25
$19.0M
$-59.8M
Q4 24
$-40.2M
Q3 24
$6.3M
$-38.1M
Q2 24
$5.4M
$-54.0M
Q1 24
$-269.0K
$-54.7M
Gross Margin
LXP
LXP
SDGR
SDGR
Q4 25
81.5%
65.7%
Q3 25
82.3%
51.6%
Q2 25
81.9%
47.8%
Q1 25
80.7%
52.3%
Q4 24
85.3%
72.6%
Q3 24
82.5%
50.2%
Q2 24
82.0%
66.2%
Q1 24
82.4%
51.6%
Operating Margin
LXP
LXP
SDGR
SDGR
Q4 25
34.6%
-19.7%
Q3 25
50.4%
-84.6%
Q2 25
33.7%
-96.6%
Q1 25
21.8%
-85.5%
Q4 24
-23.5%
Q3 24
7.9%
-193.9%
Q2 24
6.9%
-111.4%
Q1 24
1.0%
-184.3%
Net Margin
LXP
LXP
SDGR
SDGR
Q4 25
33.2%
37.3%
Q3 25
41.7%
-60.4%
Q2 25
33.2%
-78.8%
Q1 25
21.4%
-100.4%
Q4 24
-45.5%
Q3 24
7.4%
-108.1%
Q2 24
6.3%
-114.2%
Q1 24
-0.3%
-149.5%
EPS (diluted)
LXP
LXP
SDGR
SDGR
Q4 25
$0.45
Q3 25
$0.12
$-0.45
Q2 25
$0.09
$-0.59
Q1 25
$0.06
$-0.82
Q4 24
$-0.55
Q3 24
$0.02
$-0.52
Q2 24
$0.01
$-0.74
Q1 24
$-0.01
$-0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LXP
LXP
SDGR
SDGR
Cash + ST InvestmentsLiquidity on hand
$170.4M
$395.5M
Total DebtLower is stronger
$1.4B
Stockholders' EquityBook value
$2.0B
$364.1M
Total Assets
$3.5B
$726.2M
Debt / EquityLower = less leverage
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LXP
LXP
SDGR
SDGR
Q4 25
$170.4M
$395.5M
Q3 25
$229.7M
$391.2M
Q2 25
$71.0M
$450.2M
Q1 25
$70.9M
$500.3M
Q4 24
$101.8M
$352.1M
Q3 24
$55.0M
$388.7M
Q2 24
$48.7M
$377.3M
Q1 24
$293.8M
$431.1M
Total Debt
LXP
LXP
SDGR
SDGR
Q4 25
$1.4B
Q3 25
$1.5B
Q2 25
$1.5B
Q1 25
$1.5B
Q4 24
$1.6B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
LXP
LXP
SDGR
SDGR
Q4 25
$2.0B
$364.1M
Q3 25
$2.1B
$321.4M
Q2 25
$2.1B
$342.9M
Q1 25
$2.1B
$373.5M
Q4 24
$2.1B
$421.4M
Q3 24
$2.1B
$449.4M
Q2 24
$2.1B
$474.0M
Q1 24
$2.2B
$513.7M
Total Assets
LXP
LXP
SDGR
SDGR
Q4 25
$3.5B
$726.2M
Q3 25
$3.7B
$653.7M
Q2 25
$3.7B
$688.2M
Q1 25
$3.8B
$743.0M
Q4 24
$3.8B
$823.2M
Q3 24
$3.9B
$669.3M
Q2 24
$3.9B
$688.4M
Q1 24
$4.2B
$737.8M
Debt / Equity
LXP
LXP
SDGR
SDGR
Q4 25
0.66×
Q3 25
0.72×
Q2 25
0.72×
Q1 25
0.73×
Q4 24
0.75×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LXP
LXP
SDGR
SDGR
Operating Cash FlowLast quarter
$188.7M
$-16.1M
Free Cash FlowOCF − Capex
$-16.1M
FCF MarginFCF / Revenue
-18.5%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
6.56×
-0.50×
TTM Free Cash FlowTrailing 4 quarters
$12.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LXP
LXP
SDGR
SDGR
Q4 25
$188.7M
$-16.1M
Q3 25
$63.5M
$-61.9M
Q2 25
$44.3M
$-52.2M
Q1 25
$39.0M
$144.1M
Q4 24
$211.2M
$-31.1M
Q3 24
$64.6M
$-33.3M
Q2 24
$38.5M
$-53.7M
Q1 24
$38.9M
$-39.3M
Free Cash Flow
LXP
LXP
SDGR
SDGR
Q4 25
$-16.1M
Q3 25
$-62.4M
Q2 25
$-52.5M
Q1 25
$143.5M
Q4 24
$-32.0M
Q3 24
$-34.6M
Q2 24
$-54.7M
Q1 24
$-43.4M
FCF Margin
LXP
LXP
SDGR
SDGR
Q4 25
-18.5%
Q3 25
-114.8%
Q2 25
-95.9%
Q1 25
240.9%
Q4 24
-36.2%
Q3 24
-98.0%
Q2 24
-115.6%
Q1 24
-118.5%
Capex Intensity
LXP
LXP
SDGR
SDGR
Q4 25
0.0%
Q3 25
0.9%
Q2 25
0.6%
Q1 25
1.0%
Q4 24
1.0%
Q3 24
3.8%
Q2 24
2.1%
Q1 24
11.2%
Cash Conversion
LXP
LXP
SDGR
SDGR
Q4 25
6.56×
-0.50×
Q3 25
1.75×
Q2 25
1.52×
Q1 25
2.05×
Q4 24
Q3 24
10.18×
Q2 24
7.09×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LXP
LXP

Segment breakdown not available.

SDGR
SDGR

On Premise Software$44.4M51%
Drug Discovery Services$17.6M20%
Hosted Software$11.5M13%
Maintenance$6.9M8%
Professional Services$3.8M4%
July2024Agreement With Bill Melinda Gates Foundation$2.7M3%

Related Comparisons